» Articles » PMID: 37736319

Rapid-Acting Insulin Used to Treat a Case of Early Cystic Fibrosis-Related Diabetes Complicated by Post Prandial Hypoglycemia

Overview
Specialty Endocrinology
Date 2023 Sep 22
PMID 37736319
Authors
Affiliations
Soon will be listed here.
Abstract

Background/objective: Cystic fibrosis-related diabetes (CFRD) is one of the most common nonrespiratory complications of cystic fibrosis (CF). There is a lack of clinical research to provide guidance on optimal treatment regimens for various subtypes of CFRD.

Case Report: This case describes an 18-year-old woman, diagnosed with CF in infancy, who presented to our clinic for evaluation of possible CFRD and episodes of hypoglycemia. Subsequent testing revealed normal fasting glucose with elevated blood glucose levels on oral glucose tolerance test, consistent with the diagnosis of CFRD without fasting hyperglycemia. She was found to have large glycemic excursions after carbohydrate-containing meals, followed by delayed postprandial hypoglycemia.

Discussion: We initiated low-dose mealtime rapid-acting analog insulin and saw both a decrease in her postprandial hyperglycemia as well as resolution of her hypoglycemic episodes.

Conclusion: This case highlights the spectrum of pancreatic dysfunction and insulin dysregulation in CFRD as well as the benefit of prandial insulin alone as a treatment option.

Citing Articles

Editorial for September/October Issue of AACE Clinical Case Reports.

Jasim S AACE Clin Case Rep. 2023; 9(5):141.

PMID: 37736318 PMC: 10509367. DOI: 10.1016/j.aace.2023.09.001.

References
1.
Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W . Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32(9):1626-31. PMC: 2732133. DOI: 10.2337/dc09-0586. View

2.
Moran A, Brunzell C, Cohen R, Katz M, Marshall B, Onady G . Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010; 33(12):2697-708. PMC: 2992215. DOI: 10.2337/dc10-1768. View

3.
Granados A, Chan C, Ode K, Moheet A, Moran A, Holl R . Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J Cyst Fibros. 2019; 18 Suppl 2:S3-S9. DOI: 10.1016/j.jcf.2019.08.016. View

4.
Kilberg M, Sheikh S, Stefanovski D, Kubrak C, De Leon D, Hadjiliadis D . Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia. J Cyst Fibros. 2019; 19(2):310-315. PMC: 7007375. DOI: 10.1016/j.jcf.2019.07.006. View

5.
ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S19-S40. PMC: 9810477. DOI: 10.2337/dc23-S002. View